MEDICENNA THERAPEUTICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.49 CAD | +27.69% |
|
+51.83% | +492.86% |
| Apr. 26 | Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding | CI |
| Apr. 24 | Medicenna Therapeutics Up 13% After Flagging Presentations | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 21.72 | 168.5 | 270.3 | 91.69 | 61.28 | 173.4 | - | - |
| Enterprise Value (EV) 1 | 21.72 | 168.5 | 270.3 | 91.69 | 61.28 | 173.4 | 173.4 | 173.4 |
| P/E ratio | -4.22 x | -13.8 x | -14.6 x | -3.93 x | -5.5 x | -10.6 x | -9.58 x | -10.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 297 x | 94.6 x |
| EV / Revenue | - | - | - | - | - | - | 297 x | 94.6 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 8.3 x | 4.66 x | 7.17 x | 4.3 x | 1.49 x | 10.4 x | -83 x | -9.96 x |
| Nbr of stocks (in thousands) | 28,578 | 46,798 | 52,902 | 55,571 | 69,637 | 69,637 | - | - |
| Reference price 2 | 0.7600 | 3.600 | 5.110 | 1.650 | 0.8800 | 2.490 | 2.490 | 2.490 |
| Announcement Date | 6/25/19 | 5/15/20 | 5/28/21 | 6/22/22 | 6/27/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.5833 | 1.833 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.727 | -8.245 | -17.4 | -22.47 | -16.3 | -19.68 | -19.33 | -19.38 |
| Operating Margin | - | - | - | - | - | - | -3,314.08% | -1,057.2% |
| Earnings before Tax (EBT) 1 | -4.708 | -8.277 | -17.29 | -22.58 | -10.05 | -16.55 | -18.97 | -18.8 |
| Net income 1 | -4.708 | -8.277 | -17.3 | -22.58 | -10.05 | -16.3 | -19.03 | -18.87 |
| Net margin | - | - | - | - | - | - | -3,262.88% | -1,029.17% |
| EPS 2 | -0.1800 | -0.2600 | -0.3500 | -0.4200 | -0.1600 | -0.2350 | -0.2600 | -0.2467 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 6/25/19 | 5/15/20 | 5/28/21 | 6/22/22 | 6/27/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -8.233 | -4.897 | -3.127 | -4.33 | -4.733 | -4.921 | -2.319 | -4.459 | -5.437 | -4.777 | -5.125 | -5.213 | -5.266 | -5.318 | -5.371 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.178 | -4.807 | -3.206 | -4.155 | -0.896 | -1.141 | -3.856 | -2.882 | -3.723 | -4.977 | -4.986 | -5.213 | -5.266 | -5.318 | -5.371 |
| Net income 1 | -8.2 | -4.807 | -3.206 | -4.155 | -0.896 | -1.141 | -3.856 | -2.9 | -3.723 | -4.977 | -4.986 | -5.213 | -5.266 | -5.318 | -5.371 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1500 | -0.0900 | -0.0600 | -0.0700 | -0.0100 | -0.0200 | -0.0600 | -0.0400 | -0.0500 | -0.0700 | -0.0733 | -0.0700 | -0.0700 | -0.0600 | -0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 2/9/22 | 6/22/22 | 8/15/22 | 11/4/22 | 2/7/23 | 6/27/23 | 7/28/23 | 11/14/23 | 2/14/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -46.5% | -76.6% | -34.1% | -101% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.0900 | 0.7700 | 0.7100 | 0.3800 | 0.5900 | 0.2400 | -0.0300 | -0.2500 |
| Cash Flow per Share 2 | -0.3100 | -0.2800 | -0.3100 | -0.4300 | -0.2000 | -0.2300 | 0.2300 | 0.8100 |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 6/25/19 | 5/15/20 | 5/28/21 | 6/22/22 | 6/27/23 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.49
CAD
Average target price
9
CAD
Spread / Average Target
+261.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +492.86% | 127M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MDNA Stock
- Financials Medicenna Therapeutics Corp.
